TY - JOUR
T1 - Dye-based chromoendoscopy for the detection of colorectal neoplasia
T2 - meta-analysis of randomized controlled trials
AU - Antonelli, Giulio
AU - Correale, Loredana
AU - Spadaccini, Marco
AU - Maselli, Roberta
AU - Bhandari, Pradeep
AU - Bisschops, Raf
AU - Cereatti, Fabrizio
AU - Dekker, Evelien
AU - East, James E.
AU - Iacopini, Federico
AU - Jover, Rodrigo
AU - Kiesslich, Ralph
AU - Pellise, Maria
AU - Sharma, Prateek
AU - Rex, Douglas K.
AU - Repici, Alessandro
AU - Hassan, Cesare
N1 - Funding Information:
DISCLOSURE: The following authors disclosed financial relationships: G. Antonelli, L. Correale: Consultant for Alpha-Sigma. J. E. East: Clinical advisory board for Lumendi, Boston Scientific , Paion , and Satisfai Health; shareholder with Satisfai Health; speaker for Falk and Janssen; research funding from the National Institute for Health Research Oxford Biomedical Research Centre M. Pellise: Consultant for Fujifilm Europe and Norgine Iberia; speaker for Medtronic and Olympus; P. Sharma: Consultant for Bausch, Boston Scientific Corporation, CDx Labs, Covidien LP, Exact Sciences, Fujifilm Medical Systems USA, Inc, Lucid, Lumendi, Medtronic, Phathom, Olympus, Takeda, and Samsung Bioepis; Grants from or contracts with, Cosmo Pharmaceuticals, Covidien, Docbot, ERBE USA Inc, Fujifilm Holdings America Corporation, Ironwood Pharmaceuticals, Inc, Medtronic USA, Inc, and Olympus. . All other authors disclosed no financial relationships.
Publisher Copyright:
© 2022 American Society for Gastrointestinal Endoscopy
PY - 2022/9
Y1 - 2022/9
N2 - Background and Aims: Dye-based chromoendoscopy (DBC) could be effective in increasing the adenoma detection rate (ADR) in patients undergoing colonoscopy, but the technique is time-consuming and its uptake is limited. We aimed to assess the effect of DBC on ADR based on available randomized controlled trials (RCTs). Methods: Four databases were searched up to April 2022 for RCTs comparing DBC with conventional colonoscopy (CC) in terms of ADR, advanced ADR, and sessile serrated adenoma detection rate as well as the mean adenomas per patient and non-neoplastic lesions. Relative risk (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes were calculated using random-effect models. The I2 test was used for quantifying heterogeneity. Risk of bias was evaluated with the Cochrane tool. Results: Overall, 10 RCTs (5334 patients) were included. Indication for colonoscopy was screening or surveillance (3 studies) and mixed (7 studies). Pooled ADR was higher in the DBC group versus the CC group (95% CI, 48.1% [41.4%-54.8%] vs 39.3% [33.5%-46.4%]; RR, 1.20 [1.11-1.29]), with low heterogeneity (I2 = 29%). This effect was consistent for advanced ADR (RR, 1.21 [1.03-1.42]; I2 = .0%), sessile serrated adenomas (6.1% vs 3.5%; RR, 1.68 [1.15-2.47]; I2 = 9.8%), and mean adenomas per patient (MD, .24 [.17-.31]) overall and in the right-sided colon (MD, .28 [.14-.43]). A subgroup analysis considering only trials using high-definition white-light endoscopy reduced the heterogeneity while still showing a significant increase in adenoma detection with DBC: 51.6% (95% confidence interval [CI], 47.1%-56.1%) and 59.1% (95% CI, 54.7-63.3%), RR = 1.14 (95% CI, 1.06-1.23), P = .0004, I2 = .0%, P = .50. Conclusions: Meta-analysis of RCTs showed that DBC increases key quality parameters in colonoscopy, supporting its use in everyday clinical practice.
AB - Background and Aims: Dye-based chromoendoscopy (DBC) could be effective in increasing the adenoma detection rate (ADR) in patients undergoing colonoscopy, but the technique is time-consuming and its uptake is limited. We aimed to assess the effect of DBC on ADR based on available randomized controlled trials (RCTs). Methods: Four databases were searched up to April 2022 for RCTs comparing DBC with conventional colonoscopy (CC) in terms of ADR, advanced ADR, and sessile serrated adenoma detection rate as well as the mean adenomas per patient and non-neoplastic lesions. Relative risk (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes were calculated using random-effect models. The I2 test was used for quantifying heterogeneity. Risk of bias was evaluated with the Cochrane tool. Results: Overall, 10 RCTs (5334 patients) were included. Indication for colonoscopy was screening or surveillance (3 studies) and mixed (7 studies). Pooled ADR was higher in the DBC group versus the CC group (95% CI, 48.1% [41.4%-54.8%] vs 39.3% [33.5%-46.4%]; RR, 1.20 [1.11-1.29]), with low heterogeneity (I2 = 29%). This effect was consistent for advanced ADR (RR, 1.21 [1.03-1.42]; I2 = .0%), sessile serrated adenomas (6.1% vs 3.5%; RR, 1.68 [1.15-2.47]; I2 = 9.8%), and mean adenomas per patient (MD, .24 [.17-.31]) overall and in the right-sided colon (MD, .28 [.14-.43]). A subgroup analysis considering only trials using high-definition white-light endoscopy reduced the heterogeneity while still showing a significant increase in adenoma detection with DBC: 51.6% (95% confidence interval [CI], 47.1%-56.1%) and 59.1% (95% CI, 54.7-63.3%), RR = 1.14 (95% CI, 1.06-1.23), P = .0004, I2 = .0%, P = .50. Conclusions: Meta-analysis of RCTs showed that DBC increases key quality parameters in colonoscopy, supporting its use in everyday clinical practice.
UR - https://www.scopus.com/pages/publications/85135289426
U2 - 10.1016/j.gie.2022.05.002
DO - 10.1016/j.gie.2022.05.002
M3 - Review article
C2 - 35588768
SN - 0016-5107
VL - 96
SP - 411
EP - 422
JO - Gastrointestinal endoscopy
JF - Gastrointestinal endoscopy
IS - 3
ER -